JP2017514866A - Ｂｒａｆ阻害剤を使用する創傷治癒 - Google Patents

Ｂｒａｆ阻害剤を使用する創傷治癒 Download PDF

Info

Publication number
JP2017514866A
JP2017514866A JP2016566754A JP2016566754A JP2017514866A JP 2017514866 A JP2017514866 A JP 2017514866A JP 2016566754 A JP2016566754 A JP 2016566754A JP 2016566754 A JP2016566754 A JP 2016566754A JP 2017514866 A JP2017514866 A JP 2017514866A
Authority
JP
Japan
Prior art keywords
dressing
group
braf inhibitor
wound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514866A5 (enExample
Inventor
リバス アントニー
リバス アントニー
エスクイン オーディナス ヘレナ
エスクイン オーディナス ヘレナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017514866A publication Critical patent/JP2017514866A/ja
Publication of JP2017514866A5 publication Critical patent/JP2017514866A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016566754A 2014-05-06 2015-05-06 Ｂｒａｆ阻害剤を使用する創傷治癒 Pending JP2017514866A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989398P 2014-05-06 2014-05-06
US61/989,398 2014-05-06
PCT/US2015/029562 WO2015171833A1 (en) 2014-05-06 2015-05-06 Wound healing using braf inhibitors

Publications (2)

Publication Number Publication Date
JP2017514866A true JP2017514866A (ja) 2017-06-08
JP2017514866A5 JP2017514866A5 (enExample) 2018-06-21

Family

ID=54392978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566754A Pending JP2017514866A (ja) 2014-05-06 2015-05-06 Ｂｒａｆ阻害剤を使用する創傷治癒

Country Status (5)

Country Link
US (1) US20170100345A1 (enExample)
EP (1) EP3139927A4 (enExample)
JP (1) JP2017514866A (enExample)
CN (1) CN106535900A (enExample)
WO (1) WO2015171833A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530457A (ja) * 2017-08-08 2020-10-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2022519675A (ja) * 2019-02-12 2022-03-24 ルトリス ファーマ エル ティー ディー． 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2947237T3 (es) * 2016-03-10 2023-08-03 Lutris Pharma Ltd Uso de inhibidores de BRaf para el tratamiento de reacciones cutáneas
WO2017223245A1 (en) * 2016-06-21 2017-12-28 The Regents Of The University Of California Wound healing using braf inhibitors
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
US11998550B2 (en) 2017-04-20 2024-06-04 Thomas Jefferson University Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation
WO2019026065A2 (en) * 2017-07-29 2019-02-07 Lutris Pharma Ltd. NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS
US20200325543A1 (en) * 2017-11-20 2020-10-15 Tolremo Therapeutics Ag Diagnostic method
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506908A (ja) * 1996-12-20 2001-05-29 プロサイト コーポレイション 吸収性ヒドロゲル粒子および創傷用ドレッシングにおけるその使用
JP2003192598A (ja) * 2001-12-27 2003-07-09 Mikasa Seiyaku Co Ltd 創傷治療用製剤
JP2008546797A (ja) * 2005-06-22 2008-12-25 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法，およびその適応症
JP2009519917A (ja) * 2005-12-17 2009-05-21 パウル ハルトマン アクチェンゲゼルシャフト 有効成分を含む医薬組成物、及び組成物を含む創傷接触層
JP2012524058A (ja) * 2009-04-15 2012-10-11 フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
JP2013523614A (ja) * 2010-03-26 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
WO2005091891A2 (en) * 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
PL2947072T3 (pl) * 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
EP2937345B1 (en) * 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
CN103153290B (zh) * 2010-10-11 2018-01-16 普渡研究基金会 有助于伤口愈合的抗微生物制剂
WO2012068468A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
US9222137B2 (en) * 2011-05-10 2015-12-29 Trovagene, Inc. Method for monitoring minimal residual hairy cell leukemia
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
CN103520162B (zh) * 2013-10-15 2015-11-18 中国科学院上海药物研究所 达拉菲尼抑制程序性坏死和保护肝脏的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001506908A (ja) * 1996-12-20 2001-05-29 プロサイト コーポレイション 吸収性ヒドロゲル粒子および創傷用ドレッシングにおけるその使用
JP2003192598A (ja) * 2001-12-27 2003-07-09 Mikasa Seiyaku Co Ltd 創傷治療用製剤
JP2008546797A (ja) * 2005-06-22 2008-12-25 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法，およびその適応症
JP2009519917A (ja) * 2005-12-17 2009-05-21 パウル ハルトマン アクチェンゲゼルシャフト 有効成分を含む医薬組成物、及び組成物を含む創傷接触層
JP2012524058A (ja) * 2009-04-15 2012-10-11 フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
JP2013523614A (ja) * 2010-03-26 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
高水 勝: "ドレッシング材を４つの視点で整理する", 薬局, vol. 第６４巻，第１２号, JPN6019008079, 2013, pages 2984 - 2994, ISSN: 0004159168 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530457A (ja) * 2017-08-08 2020-10-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2023021241A (ja) * 2017-08-08 2023-02-10 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP7520093B2 (ja) 2017-08-08 2024-07-22 メモリアル スローン ケタリング キャンサー センター Ｍｅｋ阻害剤治療によって惹起される皮膚反応を治療するｂｒａｆ阻害剤の使用
JP2022519675A (ja) * 2019-02-12 2022-03-24 ルトリス ファーマ エル ティー ディー． 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用

Also Published As

Publication number Publication date
EP3139927A1 (en) 2017-03-15
US20170100345A1 (en) 2017-04-13
EP3139927A4 (en) 2017-12-13
CN106535900A (zh) 2017-03-22
WO2015171833A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
US20170100345A1 (en) Wound healing using braf inhibitors
US11414488B2 (en) Methods for treating cancer
US9814714B2 (en) Kinase modulation, and indications therefor
JP2020534285A (ja) 投与および処置の方法
JP2012520299A (ja) キナーゼタンパク質結合阻害剤
WO2022143628A1 (zh) 预防或治疗抗肿瘤剂相关疾病或病症的方法
JP2013541590A (ja) 皮膚の病的状態を治療するための組成物及び方法
US20190262343A1 (en) Wound healing using braf inhibitors
EP4281055A1 (en) Crystalline forms of a pyrrolopyridine-aniline compound
US8957107B2 (en) Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
TWI826738B (zh) 癌症治療方法
WO2017221142A1 (en) Wnt inhibitors for use in the treatment of fibrosis
CN111867678B (zh) 治疗黑色素瘤的方法
US20180015075A1 (en) Methods and compositions for treatment of venous malformation
CA2889010A1 (en) Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin
KR20200051690A (ko) 국소 조성물
CN115697317A (zh) Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
US20240197666A1 (en) Diterpenoid compounds that act on protein kinase c (pkc)
WO2024077358A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones.
EP4511031A1 (en) Treatment of neutrophilic dermatoses
KR20200051689A (ko) 국소 조성물 및 치료 방법
Mack et al. Stat3 is activated in skin lesions by the local application of imiquimod, a ligand of TLR7, and inhibited by the recombinant peptide aptamer rS3-PA.
TW202126631A (zh) 作為klk5/7雙重抑制劑之苯并酮化合物
Sharma SHP2/PTPN11 protein-tyrosine phosphatase promotes mast cell homeostasis and systemic mastocytosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201110